Insilico Medicine Cayman TopCo’s shares jumped on Monday after it struck an artificial intelligence-driven drug development ...

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery ...

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

In December, The Conversation hosted a webinar on AI's revolutionary role in drug discovery and development. Science and ...

DeepCyte, a techbio company building AI toxicology tools for drug development, launched today with $1.5 million in seed funding. The company is introducing two solutions to help biopharma teams detect ...

In his keynote address, Prof. Sastry emphasized that AI is dramatically accelerating drug discovery timelines, reducing costs, and enabling precision-driven research outcomes.

As a drug moves through research and regulatory processes, any mistakes in the data will be compounded. Small gaps that a ...

Y ou’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence ...

When patient safety, regulatory approval and real-world effectiveness are on the line, AI can't act autonomously.

The convergence of two already fantastic industries is creating an incredible opportunity.